Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108485 - SOLID FORM, CRYSTALLINE FORM, AND CRYSTAL FORM A OF FXR AGONIST, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Publication Number WO/2020/108485
Publication Date 04.06.2020
International Application No. PCT/CN2019/120992
International Filing Date 26.11.2019
IPC
C07D 405/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
A61K 31/4709 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines containing further heterocyclic rings
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 31/4709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines and containing further heterocyclic rings
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
Applicants
  • 南京明德新药研发有限公司 MEDSHINE DISCOVERY INC. [CN]/[CN]
Inventors
  • 李小林 LI, Xiaolin
  • 李鹏 LI, Peng
  • 贺海鹰 HE, Haiying
Agents
  • 上海弼兴律师事务所 SHANGHAI BESHINING LAW OFFICE
Priority Data
201811418346.826.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) SOLID FORM, CRYSTALLINE FORM, AND CRYSTAL FORM A OF FXR AGONIST, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
(FR) FORME SOLIDE, FORME CRISTALLINE ET FORME CRISTALLINE A D'AGONISTE DE FXR, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 一种FXR激动剂的固体形式、结晶形式、A晶型及其制备方法和应用
Abstract
(EN)
Disclosed are a solid form, a crystalline form, and crystal form A of a compound of formula (I) used as an FXR agonist, and a preparation method therefor. Also comprised is an application of the compound of formula (I) in preparation of a medication for treating nonalcoholic steatohepatitis (NASH).
(FR)
L'invention concerne une forme solide, une forme cristalline et une forme cristalline A d'un composé de formule (I) utilisé en tant qu'agoniste de FXR, et un procédé de préparation associé. L'invention concerne également une utilisation du composé de formule (I) dans la préparation d'un médicament pour le traitement de la stéatohépatite non alcoolique (SHNA).
(ZH)
本发明公开了一种作为FXR受体激动剂的式(I)化合物的固体形式、结晶形式、A晶型及其制备方法,还包括式(I)化合物的在制备治疗非酒精性脂肪肝炎(NASH)药物中的应用。
Latest bibliographic data on file with the International Bureau